M-CPP and Fenfluramine in Cocaine Addicts - 3

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000314

Purpose

The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: M-CPP	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts

Resource links provided by NLM:

Drug Information available for: Fenfluramine hydrochloride Fenfluramine

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Drug use
Hospitalization, arrests, jail, employment, psychiataric symptoms

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	25 Years to 50 Years
Genders Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000314

Locations

United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

Laure Buydens-Branchey, M.D.

Department of Veterans Affairs

More Information

No publications provided

Study ID Numbers:	NIDA-09468-3, R01-09468-3
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000314 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Serotonin Agents
Molecular Mechanisms of Pharmacological Action
Mental Disorders

Physiological Effects of Drugs
Substance-Related Disorders
Disorders of Environmental Origin
Fenfluramine
Serotonin Uptake Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 27, 2009